The global coronavirus pandemic has created a huge spike in mental health conditions. This summer, the Centers for Disease Control reported 11% of American adults considered suicide, while a whopping 40% said they were struggling with mental health or substance abuse. Companies like MindMed (MMEDF) are creating psychedelic drugs to help people battle these mental health issues. The New York-based biotech startup is conducting clinical trials of drugs including LSD and psilocybin, to treat anxiety, depression and opioid addiction. “I think that psychedelic medicines offer a new paradigm in mental health,” MindMed’s co-founder and co-CEO JR Rahn told Yahoo Finance Live. “Traditional medicines that are treating things like depression, addiction, and anxiety really are seeking to numb and mask the issues that surround these illnesses. So, things like Xanax, while they might make you feel better, they can also be highly addictive and are not dealing with the underlying problem.” https://finance-yahoo-com.cdn.ampproject.org/c/s/finance.yahoo.com/amphtml/news/wall-street-eyes-mental-health-as-the-next-great-growth-story-132619645.html